Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Atria plans EUR 16m investment in its Kauhajoki plant to modernise production and reorganise beef pr...
Redeye comments on the Q2 report. Top-line figures came in broadly in line with our expectations.
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for diffic...
Redeye is positive to GomSpace’s Q2 report published this morning, where the company slightly exceed...
* Pome project schedule delayed * Lower-than-expected project margins in Pome and Pienava * We cut '...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
Redeye updates its view on Xbrane following its Q2 report.
Redeye updates on Gentoo Media after weaker-than-expected Q2 results and lowered full-year 2025 guid...
Redeye provides an update following Corline’s Q2 2025 report.
* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...
* Top-line pressure persisting, better cost control * We cut '25e-'27e adj.
Redeye gives an initial comment on the positive news that BioArctic has signed an “option, collabora...
* '25e-'27e sales cut by 6-1% * Market softness persists, delaying customer decisions * Cost-cutting...
Redeye provides a research update following the Q2 report published by Isofol earlier today.
* Comps to become easier in '26e * Cutting '25e-'27e adj.
* Q2 adj. EBITDA 25% below consensus on 12% sales miss * FY guidance cut; cons '25e EBITDA to come d...
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
